Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Belatacept

CMV infection: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shertel TL, et al. Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation. American Journal of Transplantation 20 (Suppl. 3): 925 abstr. B-110, Apr 2020. Available from: URL: http://doi.org/10.1111/ajt.16171 [abstract] Shertel TL, et al. Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation. American Journal of Transplantation 20 (Suppl. 3): 925 abstr. B-110, Apr 2020. Available from: URL: http://​doi.​org/​10.​1111/​ajt.​16171 [abstract]
Metadaten
Titel
Belatacept
CMV infection: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49452-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Belatacept

Case report

Natalizumab

Case report

Aflibercept